HK1205193A1 - Recombinant n-glycosylated proteins from procaryotic cells n- - Google Patents

Recombinant n-glycosylated proteins from procaryotic cells n-

Info

Publication number
HK1205193A1
HK1205193A1 HK15105466.7A HK15105466A HK1205193A1 HK 1205193 A1 HK1205193 A1 HK 1205193A1 HK 15105466 A HK15105466 A HK 15105466A HK 1205193 A1 HK1205193 A1 HK 1205193A1
Authority
HK
Hong Kong
Prior art keywords
recombinant
proteins
glycosylated proteins
procaryotic cells
glycosylated
Prior art date
Application number
HK15105466.7A
Other languages
Chinese (zh)
Inventor
Markus Aebi
Michael Kowarik
Umesh Ahuja
Original Assignee
Eth Zrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zrich filed Critical Eth Zrich
Publication of HK1205193A1 publication Critical patent/HK1205193A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to recombinant N-glycosylated proteins, comprising one or more introduced N-glycosylated optimized amino acid sequence(s), pharmaceutical compositions comprising said proteins as well as corresponding vectors and host cells. In addition, the present invention provides methods for producing said proteins.
HK15105466.7A 2005-05-11 2015-06-09 Recombinant n-glycosylated proteins from procaryotic cells n- HK1205193A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05010276 2005-05-11

Publications (1)

Publication Number Publication Date
HK1205193A1 true HK1205193A1 (en) 2015-12-11

Family

ID=37396912

Family Applications (3)

Application Number Title Priority Date Filing Date
HK08109020.7A HK1113588A1 (en) 2005-05-11 2008-08-14 Recombinant n-glycosylated proteins from procaryotic cells
HK11111186.8A HK1156983A1 (en) 2005-05-11 2011-10-19 Recombinant n-glycosylated proteins from procaryotic cells n-
HK15105466.7A HK1205193A1 (en) 2005-05-11 2015-06-09 Recombinant n-glycosylated proteins from procaryotic cells n-

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK08109020.7A HK1113588A1 (en) 2005-05-11 2008-08-14 Recombinant n-glycosylated proteins from procaryotic cells
HK11111186.8A HK1156983A1 (en) 2005-05-11 2011-10-19 Recombinant n-glycosylated proteins from procaryotic cells n-

Country Status (19)

Country Link
US (3) US8753864B2 (en)
EP (3) EP1888761B1 (en)
JP (3) JP5356807B2 (en)
KR (2) KR101524636B1 (en)
CN (2) CN103396478B (en)
AT (1) ATE483027T1 (en)
AU (1) AU2006245969B8 (en)
CA (1) CA2607595C (en)
CY (1) CY1116285T1 (en)
DE (1) DE602006017207D1 (en)
DK (2) DK1888761T3 (en)
ES (3) ES2703061T3 (en)
HK (3) HK1113588A1 (en)
HR (1) HRP20150312T1 (en)
IL (2) IL187293A (en)
PL (1) PL2311972T3 (en)
PT (2) PT2311972E (en)
SI (1) SI2311972T1 (en)
WO (1) WO2006119987A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
MXPA05010773A (en) 2003-04-09 2005-12-12 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods.
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0506741A (en) 2004-01-08 2007-05-15 Neose Technologies Inc glycosylation of peptides linked to the
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8092788B2 (en) * 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
JP5948627B2 (en) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー Fibroblast growth factor (FGF) remodeling and carbohydrate pegylation
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101516388B (en) 2006-07-21 2012-10-31 诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag Methods of treatment using glycopegylated g-csf
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
CN107119095B (en) 2008-01-03 2022-07-05 康乃尔研究基金会有限公司 Glycosylated protein expression in prokaryotes
JP5647899B2 (en) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ Glycoconjugation of polypeptides using oligosaccharyltransferase
CA2716187C (en) * 2008-02-20 2020-01-07 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
EP2257311B1 (en) 2008-02-27 2014-04-16 Novo Nordisk A/S Conjugated factor viii molecules
US9309493B2 (en) * 2009-03-27 2016-04-12 Eidgenoessische Technische Hochschule Zurich Salmonella enterica presenting C. jejuni N-glycan or derivatives thereof
NO2501406T3 (en) * 2009-11-19 2018-05-19
AU2011214871A1 (en) 2010-02-11 2012-09-06 The Governors Of The University Of Alberta N-Linked Glycan Compounds.
HUE037956T2 (en) 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Capsular gram-positive bacteria bioconjugate vaccines
US20130266604A1 (en) * 2010-09-03 2013-10-10 The Governors of the University of Alberta a non-profit educational institution Peptide containing multiple n-linked glycosylation sequons
US20140336366A1 (en) 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
EP3444352B1 (en) 2012-11-07 2020-12-16 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
IL273685B2 (en) 2013-01-17 2023-10-01 X4 Pharmaceuticals Austria Gmbh IMMUNOGENS AND VACCINES COMPRISING O25b ANTIGENS
CA2923957C (en) 2013-01-18 2021-08-31 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EP2970128B1 (en) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
RU2671473C2 (en) * 2013-04-05 2018-10-31 Де Гавенерс Оф Де Юниверсити Оф Альберта Vaccine against campylobacteriosis
JP2016533719A (en) * 2013-10-11 2016-11-04 グリコヴァキシン アーゲー Host cell modification method
SG11201606889PA (en) 2014-02-24 2016-09-29 Glycovaxyn Ag Novel polysaccharide and uses thereof
EP3131577B1 (en) * 2014-04-17 2020-04-22 GlaxoSmithKline Biologicals S.A. Modified host cells and uses thereof
US10307474B2 (en) 2014-08-08 2019-06-04 Glaxosmithkline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
EP3240895B1 (en) * 2014-12-30 2022-01-26 GlaxoSmithKline Biologicals S.A. Compositions and methods for protein glycosylation
TWI715617B (en) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 Methods and compositions for immune protection against extra-intestinal pathogenic e. coli
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (en) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC
CN110520153B (en) * 2017-01-27 2024-04-02 佛罗里达大学研究基金公司 Food-safe vaccine for controlling Salmonella enterica and reducing Campylobacter in birds
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
WO2019204346A1 (en) 2018-04-16 2019-10-24 Northwestern University METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES
JP2022513458A (en) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Modified carrier protein for O-linked glycosylation
SG11202110303XA (en) 2019-03-18 2021-10-28 Janssen Pharmaceuticals Inc Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
UY38616A (en) * 2019-03-18 2020-09-30 Janssen Pharmaceuticals Inc BIOCONJUGATES OF POLYSACCHARIDES OF E. COLI ANTIGEN-O AND METHODS OF PRODUCTION AND USE OF THE SAME.
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
IL294445B2 (en) 2020-01-16 2023-10-01 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
EP4168040A1 (en) 2020-06-18 2023-04-26 GlaxoSmithKline Biologicals S.A. Shigella-tetravalent (shigella4v) bioconjugate
US20230226175A1 (en) 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
WO2022058945A1 (en) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
IL303954A (en) 2021-01-12 2023-08-01 Janssen Pharmaceuticals Inc Fimh mutants, compositions therewith and use thereof
BR112023019874A2 (en) 2021-04-01 2023-11-07 Janssen Pharmaceuticals Inc PRODUCTION OF E. COLI O18 BIOCONJUGATES
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67786T1 (en) 1984-08-01 1991-10-15 Boehringer Ingelheim Int NEW GENETIC SEQUENCES ENCODED BY TYPE I INTERFERON PEPTIDES AND THEIR PRODUCING ORGANISMS.
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
WO1994026906A2 (en) 1993-05-14 1994-11-24 The Upjohn Company CLONED DNA ENCODING A UDP-GALNAc:POLYPEPTIDE,N-ACETYLGALACTOS AMINYLTRANSFERASE
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
AU3508300A (en) 1999-03-02 2000-09-21 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
HUP0302299A2 (en) 2000-05-12 2003-10-28 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
EP2028275A3 (en) 2000-06-30 2009-05-06 VIB vzw Protein glycosylation modification in pichia pastoris
DE10113573A1 (en) * 2001-03-20 2002-02-28 Messer Griesheim Gmbh Process for the regeneration of sulfuric acid from sulfur-containing residues
US20040265954A1 (en) 2002-03-07 2004-12-30 Markus Aebi System and method for the production of recombinant proteins
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
US7598354B2 (en) * 2002-08-01 2009-10-06 National Research Council Of Canada Campylobacter glycans and glycopeptides

Also Published As

Publication number Publication date
CY1116285T1 (en) 2017-02-08
DK2311972T3 (en) 2015-04-27
HK1156983A1 (en) 2016-11-25
JP5356807B2 (en) 2013-12-04
EP2311972B1 (en) 2015-01-21
DK1888761T3 (en) 2010-11-01
KR20140019482A (en) 2014-02-14
EP2853600A1 (en) 2015-04-01
IL187293A (en) 2013-06-27
KR20080048990A (en) 2008-06-03
JP2012100678A (en) 2012-05-31
EP2311972A1 (en) 2011-04-20
PL2311972T3 (en) 2015-08-31
KR101524636B1 (en) 2015-06-03
CA2607595C (en) 2018-11-27
US8753864B2 (en) 2014-06-17
CN101360831B (en) 2013-07-10
PT1888761E (en) 2011-01-03
PT2311972E (en) 2015-05-13
KR101408653B1 (en) 2014-06-17
CN103396478B (en) 2016-09-28
IL226857A (en) 2017-08-31
EP1888761A2 (en) 2008-02-20
ES2703061T3 (en) 2019-03-06
WO2006119987A2 (en) 2006-11-16
JP2014042533A (en) 2014-03-13
AU2006245969B8 (en) 2011-08-25
AU2006245969A1 (en) 2006-11-16
IL226857A0 (en) 2013-07-31
EP1888761B1 (en) 2010-09-29
IL187293A0 (en) 2008-04-13
DE602006017207D1 (en) 2010-11-11
US20160326563A1 (en) 2016-11-10
US9551019B2 (en) 2017-01-24
CN101360831A (en) 2009-02-04
US20100062484A1 (en) 2010-03-11
AU2006245969B2 (en) 2011-06-02
JP2008539743A (en) 2008-11-20
HK1113588A1 (en) 2008-10-10
ES2535084T3 (en) 2015-05-05
ES2353814T3 (en) 2011-03-07
HRP20150312T1 (en) 2015-07-31
JP5687637B2 (en) 2015-03-18
US20140323700A1 (en) 2014-10-30
EP2853600B1 (en) 2018-09-19
CN103396478A (en) 2013-11-20
JP5827303B2 (en) 2015-12-02
WO2006119987A3 (en) 2007-03-08
SI2311972T1 (en) 2015-08-31
CA2607595A1 (en) 2006-11-16
ATE483027T1 (en) 2010-10-15

Similar Documents

Publication Publication Date Title
HK1205193A1 (en) Recombinant n-glycosylated proteins from procaryotic cells n-
MX2008001865A (en) Albumin fusion proteins.
MX336807B (en) Compositions and methods for producing a composition.
MX2009002816A (en) Albumin fusion proteins.
WO2005003296A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
MX2010005783A (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same.
WO2007146038A3 (en) Albumin fusion proteins
NZ591415A (en) Haemophilus influenzae type B
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
IL213319A (en) Polylysine peptides for use in the treatment of bacterial infections
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
WO2007103490A3 (en) System for the expression of orthogonal translation components in eubacterial host cells
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
MX2010004371A (en) Streptomyces protease.
WO2008136865A3 (en) (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
EP1978994A4 (en) Bmp-7 variant compositions, methods and uses
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
TW200734350A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2006017355A3 (en) Improved aprotinin variants
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
TW200700076A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same